|
hepatocellular carcinoma |
38 |
|
liver transplantation |
25 |
|
medical sciences |
23 |
|
hepatectomy |
20 |
|
surgery |
20 |
|
transarterial chemoembolization |
19 |
|
gastroenterology |
17 |
|
gastroenterology medical sciences |
17 |
|
cirrhosis |
16 |
|
survival analysis |
16 |
|
hcc |
15 |
|
outcomes |
14 |
|
liver transplant |
13 |
|
survival |
13 |
|
adult |
12 |
|
liver resection |
12 |
|
recurrence |
12 |
|
acute flare |
11 |
|
cancer staging |
11 |
|
cancer survival |
11 |
|
controlled study |
11 |
|
decompensation |
11 |
|
hepatitis |
11 |
|
hepatocellular carcinoma (hcc) |
11 |
|
high-intensity focused ultrasound |
11 |
|
liver failure |
11 |
|
long-term outcome |
11 |
|
meld |
11 |
|
portal vein |
11 |
|
ablation |
10 |
|
alpps |
10 |
|
bridging therapy |
10 |
|
humans |
10 |
|
liver cancer |
10 |
|
living donor liver transplantation |
10 |
|
molecular biology |
10 |
|
molecular pathology |
10 |
|
new technology |
10 |
|
radiofrequency ablation |
10 |
|
resection |
10 |
|
signaling |
10 |
|
sorafenib |
10 |
|
11c-acetate |
9 |
|
blood transfusion |
9 |
|
cancer invasion |
9 |
|
catheter ablation |
9 |
|
contrast ct |
9 |
|
hepatitis b |
9 |
|
hifu |
9 |
|
laparoscopic liver resection |
9 |
|
male |
9 |
|
milan criteria |
9 |
|
morbidity |
9 |
|
mortality |
9 |
|
neoplasm recurrence, local - surgery |
9 |
|
non-invasive treatment |
9 |
|
pet/ct |
9 |
|
prognosis |
9 |
|
stereotactic body radiation therapy |
9 |
|
acetic acid c 11 |
8 |
|
advanced cancer |
8 |
|
advanced hepatocellular carcinoma |
8 |
|
antiviral agents - adverse effects - therapeutic use |
8 |
|
bile ducts - surgery |
8 |
|
biliary anastomotic stricture |
8 |
|
cadaver donor |
8 |
|
cancer recurrence |
8 |
|
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
|
carcinoma, hepatocellular - mortality - therapy |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
cardiac function |
8 |
|
chemoembolization, therapeutic - adverse effects - mortality |
8 |
|
colorectal cancer |
8 |
|
deceased donor liver transplantation |
8 |
|
disease severity |
8 |
|
elderly |
8 |
|
endocrinology |
8 |
|
fluorodeoxyglucose f 18 |
8 |
|
gene mutation |
8 |
|
gist |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
hepatectomy - methods |
8 |
|
hepatitis b infection |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
infusions, intra-arterial |
8 |
|
liver |
8 |
|
liver cirrhosis |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver metastasis |
8 |
|
liver neoplasms - complications/diagnosis - surgery |
8 |
|
liver neoplasms - mortality - therapy |
8 |
|
living donor |
8 |
|
next-generation sequencing |
8 |
|
prevention |
8 |
|
rsk2 |
8 |
|
seroconversion (sc) |
8 |
|
thrombosis - diagnosis - etiology - surgery |
8 |
|
tki |
8 |
|
tomography, x-ray computed |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
unresectable |
8 |
|
waiting list |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
abdominal surgery |
7 |
|
adjuvant therapy |
7 |
|
advanced cirrhosis |
7 |
|
american society of anaesthesiologists (asa) |
7 |
|
anti-angiogenesis |
7 |
|
biliary reconstruction |
7 |
|
biomarkers |
7 |
|
carcinoma, hepatocellular - diagnosis - pathology - surgery |
7 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
7 |
|
cardiac surgery |
7 |
|
catheters, indwelling |
7 |
|
child-pugh a |
7 |
|
cholecystitis, acute - surgery |
7 |
|
cholecystostomy - instrumentation - methods |
7 |
|
cohort studies |
7 |
|
combined modality therapy |
7 |
|
combined resection |
7 |
|
complication |
7 |
|
cytology and histology |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
deceased-donor liver transplantation |
7 |
|
domino liver transplant |
7 |
|
endoscopic retrograde cholangiopancreatography |
7 |
|
entecavir |
7 |
|
experience |
7 |
|
extended criteria organ |
7 |
|
general surgery |
7 |
|
graft-to-recipient weight ratio |
7 |
|
head of pancreas |
7 |
|
hepatitis b vaccination |
7 |
|
hepatorenal syndrome |
7 |
|
high-intensity focused ultrasound ablation - methods |
7 |
|
icc |
7 |
|
indocyanine green clearance |
7 |
|
limon |
7 |
|
liver neoplasms - diagnosis - pathology - surgery |
7 |
|
liver neoplasms - mortality - pathology - therapy |
7 |
|
living donor liver transplant |
7 |
|
long-term survival |
7 |
|
medicine & public health |
7 |
|
middle aged |
7 |
|
model for end-stage liver disease |
7 |
|
oncology medical sciences |
7 |
|
palliative care |
7 |
|
percutaneous transhepatic cholecystostomy (ptc) |
7 |
|
portal vein resection |
7 |
|
pulse spectrophotometry |
7 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
7 |
|
recurrent hcc |
7 |
|
retransplantation |
7 |
|
retrospective studies |
7 |
|
right liver graft |
7 |
|
right-lobe |
7 |
|
small-for-size syndrome |
7 |
|
survival outcomes |
7 |
|
thalidomide |
7 |
|
thoracic surgery |
7 |
|
transthyretin |
7 |
|
treatment outcome |
7 |
|
usg-guided |
7 |
|
val30ala |
7 |
|
vascular surgery |
7 |
|
whipple operation |
7 |
|
acute pancreatitis |
6 |
|
anastomosis, surgical |
6 |
|
antiviral therapy |
6 |
|
asian |
6 |
|
bile leak |
6 |
|
biliary complications |
6 |
|
biliary stricture |
6 |
|
breast cancer |
6 |
|
cancer stem cells |
6 |
|
carcinoma |
6 |
|
carcinoma, hepatocellular - epidemiology - surgery |
6 |
|
carcinoma, hepatocellular - surgery |
6 |
|
case-matched study |
6 |
|
cdk1 inhibitor |
6 |
|
cholangiocarcinoma |
6 |
|
cholangiograms |
6 |
|
cholestasis - etiology |
6 |
|
close resection margin |
6 |
|
complex liver resection |
6 |
|
desmosplastic reaction |
6 |
|
diagnostic imaging |
6 |
|
donor hepatectomy |
6 |
|
duct-to-duct anastomosis |
6 |
|
ductal anomaly |
6 |
|
en-bloc resection |
6 |
|
end-stage liver disease |
6 |
|
endoscopic retrograde cholangiography |
6 |
|
endoscopic treatment |
6 |
|
erc |
6 |
|
family history |
6 |
|
graft |
6 |
|
graft survival |
6 |
|
graft-weight-to-recipient-weight ratio |
6 |
|
hepaticojejunostomy |
6 |
|
hepatocellular |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
hong kong - epidemiology |
6 |
|
inflow |
6 |
|
intrahepatic cholangiocarcinoma |
6 |
|
invasion |
6 |
|
jnk |
6 |
|
keywords |
6 |
|
laparoscopic resection |
6 |
|
laparoscopy |
6 |
|
ldlt |
6 |
|
liver neoplasms - epidemiology - surgery |
6 |
|
liver neoplasms - surgery |
6 |
|
liver resection (lr) |
6 |
|
liver transplantation (lt) |
6 |
|
liver transplantation - adverse effects |
6 |
|
liver transplantation - methods |
6 |
|
liver transplantation - statistics and numerical data |
6 |
|
living |
6 |
|
living donors |
6 |
|
living-donor liver transplantation |
6 |
|
lung metastasis |
6 |
|
metastases |
6 |
|
modulation |
6 |
|
nomogram |
6 |
|
pdx models |
6 |
|
pediatric donor |
6 |
|
post-transplant recurrence |
6 |
|
prediction |
6 |
|
predictive model |
6 |
|
ptbd |
6 |
|
radiofrequency ablation (rfa) |
6 |
|
right liver donation |
6 |
|
right-liver |
6 |
|
risk factor |
6 |
|
ro3306 |
6 |
|
simultaneous resection |
6 |
|
size |
6 |
|
small-for-size grafts |
6 |
|
stage resection |
6 |
|
standard |
6 |
|
stc1 |
6 |
|
synchronous colorectal liver metastasis |
6 |
|
transplantation |
6 |
|
tumour thrombus |
6 |
|
adjuvant chemotherapy |
5 |
|
aged |
5 |
|
alagille syndrome |
5 |
|
alpha-fetoprotein (afp) |
5 |
|
amyloid neuropathies, familial - surgery |
5 |
|
angioplasty - methods |
5 |
|
animal experiment |
5 |
|
animal model |
5 |
|
anterior approach |
5 |
|
apoptosis |
5 |
|
augmented reality |
5 |
|
bile duct atresia |
5 |
|
bile duct obstruction |
5 |
|
bile duct reconstruction |
5 |
|
bile leakage |
5 |
|
biliary obstruction |
5 |
|
carcinoma, hepatocellular - mortality - surgery |
5 |
|
catheter ablation - methods |
5 |
|
cell proliferation |
5 |
|
colorectal liver metastasis |
5 |
|
complications |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
double bypass |
5 |
|
dual portal vein |
5 |
|
endoscopic sphicterotomy |
5 |
|
esomeprazole |
5 |
|
female |
5 |
|
follow-up studies |
5 |
|
gastrointestinal hemorrhage |
5 |
|
graft failure |
5 |
|
hemostasis |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatic malignancy |
5 |
|
hepatic veins - surgery |
5 |
|
hepatopancreatoduodenectomy |
5 |
|
iatrogenic disease - prevention and control |
5 |
|
laparoscopic hepatectomy |
5 |
|
live donor liver transplantation |
5 |
|
liver neoplasms - mortality - surgery |
5 |
|
liver remnant |
5 |
|
living-donor liver re-transplantation |
5 |
|
lobectomy |
5 |
|
logistic models |
5 |
|
malignancy |
5 |
|
meld score biliary atresia |
5 |
|
meta-analysis |
5 |
|
metachronous primary hcc |
5 |
|
metal stent |
5 |
|
multivariate analysis |
5 |
|
neoplasms, second primary - mortality - surgery |
5 |
|
oncological outcomes |
5 |
|
outcome |
5 |
|
pancreatic cancer |
5 |
|
pancreaticojejunostomy |
5 |
|
pancreatoduodenectomy |
5 |
|
papillotomy |
5 |
|
peld score |
5 |
|
portal vein - anatomy and histology - surgery |
5 |
|
portal vein reconstruction |
5 |
|
post-hepatectomy |
5 |
|
post-operative complication |
5 |
|
predicting scoring system |
5 |
|
radiography, abdominal |
5 |
|
reconstructive surgical procedures - methods |
5 |
|
remnant |
5 |
|
renal transplantation |
5 |
|
reoperation |
5 |
|
residual |
5 |
|
risk factors |
5 |
|
segmentectomy |
5 |
|
spleen - injuries - pathology - radiography - surgery |
5 |
|
tissue and organ harvesting - methods |
5 |
|
toce |
5 |
|
vascular surgical procedures - methods |
5 |
|
wedge resection |
5 |
|
acute rejection |
4 |
|
allergology and immunology |
4 |
|
alpha-fetoprotein |
4 |
|
antibody-mediated rejection |
4 |
|
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
|
blood vessel prosthesis implantation |
4 |
|
body mass index |
4 |
|
carcinoma, hepatocellular - pathology |
4 |
|
carcinoma, hepatocellular - pathology - radiography - surgery |
4 |
|
cholesterol |
4 |
|
clonorchis sinensis |
4 |
|
colonic neoplasms - secondary - surgery |
4 |
|
colonoscopy |
4 |
|
dyslipidemia |
4 |
|
emergencies |
4 |
|
end stage liver disease - surgery - virology |
4 |
|
fasting glucose |
4 |
|
fatty change |
4 |
|
fatty liver - pathology - radiography |
4 |
|
gore-tex graft |
4 |
|
graft occlusion, vascular - diagnosis - etiology - physiopathology - surgery |
4 |
|
grafts |
4 |
|
hepatic veins - physiopathology - radiography - surgery |
4 |
|
hepatitis b, chronic - complications |
4 |
|
immunosuppression |
4 |
|
kidney transplantation |
4 |
|
left lobe graft |
4 |
|
lipoprotein |
4 |
|
liver - pathology - radiography - surgery |
4 |
|
liver circulation |
4 |
|
liver graft |
4 |
|
liver neoplasms - pathology - radiography - surgery |
4 |
|
liver transplantation - adverse effects - methods |
4 |
|
neoplasm invasiveness |
4 |
|
orthotopic liver transplantation |
4 |
|
phlebography - methods |
4 |
|
pneumocystis jirovecii |
4 |
|
pneumocystis pneumonia |
4 |
|
portal vein - pathology - radiography - surgery |
4 |
|
portal vein invasion |
4 |
|
post-liver transplant |
4 |
|
primary biliary cirrhosis |
4 |
|
review |
4 |
|
right lobe |
4 |
|
right lobe graft |
4 |
|
small for size liver graft |
4 |
|
steatotic donor |
4 |
|
surgery medical sciences |
4 |
|
time factors |
4 |
|
transplants |
4 |
|
triglyceride |
4 |
|
vein graft |
4 |
|
vena cava, inferior - surgery |
4 |
|
allograft |
3 |
|
amyloidosis |
3 |
|
chemotherapy |
3 |
|
cholestasis |
3 |
|
combined |
3 |
|
erectile dysfunction |
3 |
|
hbv |
3 |
|
hcv |
3 |
|
heart |
3 |
|
hepatocellular cancer |
3 |
|
heterogeneity |
3 |
|
hypogonadism |
3 |
|
living donation |
3 |
|
multifocal hcc |
3 |
|
pancreatic neoplasms |
3 |
|
practice guideline |
3 |
|
radiotherapy |
3 |
|
salvage transplantation |
3 |
|
sequential |
3 |
|
sexual dysfunction |
3 |
|
small for size syndrome |
3 |
|
stemness |
3 |
|
tumor recurrence |
3 |
|
ambulatory surgical procedures |
2 |
|
anamnesis |
2 |
|
antineoplastic agents - therapeutic use |
2 |
|
axillary dissection |
2 |
|
bile duct |
2 |
|
bile duct stricture |
2 |
|
biliary complication |
2 |
|
blood clotting |
2 |
|
breast neoplasms - drug therapy - pathology - surgery |
2 |
|
case report |
2 |
|
cholecystectomy, laparoscopic |
2 |
|
chronic hepatitis b |
2 |
|
day surgery centre |
2 |
|
end-stage liver diseases |
2 |
|
estimated standard liver volume |
2 |
|
false-negative rate |
2 |
|
feasibility studies |
2 |
|
hepatocellular cholangiocarcinoma |
2 |
|
hilar plate |
2 |
|
laparoscopic cholecystectomy |
2 |
|
lardiac stab injury |
2 |
|
liver - transplantation - complications |
2 |
|
liver transection |
2 |
|
low-pressure pneumoperitoneum |
2 |
|
lymphatic mapping |
2 |
|
outcome assessment (health care) |
2 |
|
percutaneous transhepatic biliary drainage |
2 |
|
pericardiocentesis |
2 |
|
postoperative pain |
2 |
|
propofol |
2 |
|
reoperation - statistics and numerical data |
2 |
|
resection margin |
2 |
|
right lobe living donor liver transplantation |
2 |
|
sentinel lymph node biopsy |
2 |
|
standard-pressure pneumoperitoneum |
2 |
|
subxiphoid pericardial window |
2 |
|
thoracotomy |
2 |
|
transoesophageal echocardiography |
2 |
|
trisectionectomy |
2 |
|
ventricular septal laceration |
2 |
|
acute liver failure |
1 |
|
associating liver partition and portal vein ligation in staged hepatectomy |
1 |
|
clinical outcome |
1 |
|
clinical outcomes |
1 |
|
fulminant hepatitis |
1 |
|
hepatic resection |
1 |
|
hepatitis e |
1 |
|
inflow modulation |
1 |
|
laparoscopic donor hepatectomy |
1 |
|
liver metastases |
1 |
|
living donor liver transplantatio |
1 |
|
mammalian target of rapamycin inhibitor |
1 |
|
minimally invasive surgery |
1 |
|
neoadjuvant therapy |
1 |
|
portal vein embolization |
1 |
|
portal vein ligation |
1 |
|
sarcopenia |
1 |
|
surgical indication |
1 |
|
surgical outcomes |
1 |
|
targeted agent |
1 |
|
targeted therapy |
1 |
|
transarterial radioembolization |
1 |
|
vascular invasion |
1 |
